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Cardiac LXRa protects against pathological cardiac
hypertrophy and dysfunction by enhancing glucose
uptake and utilization
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Abstract
Pathological cardiac hypertrophy is characterized by a shift in
metabolic substrate utilization from fatty acids to glucose, but the
molecular events underlying the metabolic remodeling remain
poorly understood. Here, we investigated the role of liver X receptors
(LXRs), which are key regulators of glucose and lipid metabolism, in
cardiac hypertrophic pathogenesis. Using a transgenic approach in
mice, we show that overexpression of LXRa acts to protect the heart
against hypertrophy, fibrosis, and dysfunction. Gene expression
profiling studies revealed that genes regulating metabolic pathways
were differentially expressed in hearts with elevated LXRa. Function-
ally, LXRa overexpression in isolated cardiomyocytes and murine
hearts markedly enhanced the capacity for myocardial glucose
uptake following hypertrophic stress. Conversely, this adaptive
response was diminished in LXRa-deficient mice. Transcriptional
changes induced by LXRa overexpression promoted energy-
independent utilization of glucose via the hexosamine biosynthesis
pathway, resulting in O-GlcNAc modification of GATA4 and Mef2c
and the induction of cytoprotective natriuretic peptide expression.
Our results identify LXRa as a key cardiac transcriptional regulator
that helps orchestrate an adaptive metabolic response to chronic
cardiac stress, and suggest that modulating LXRa may provide a
unique opportunity for intervening in myocyte metabolism.
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Introduction
Pathological cardiac hypertrophy and remodeling ensue in
response to sustained elevations in hemodynamic workload (Frey
& Olson, 2003). A hallmark of this remodeling process is the
alteration in myocardial energy metabolism which is necessitated
by increased energy demand (Neubauer, 2007; Ventura-Clapier
et al, 2011). Under normal physiological conditions, the heart
predominantly consumes fatty acids (FA), whereas various stres-
sors trigger a compensatory shift toward glucose, the preferred
substrate for its oxygen-sparing effect in ATP production (Stanley
et al, 2005; Opie & Knuuti, 2009). Despite the success of current
pharmacological strategies which aim to reduce afterload and
hypertrophic growth using beta blockers and inhibitors of the
renin–angiotensin–aldosterone system, heart failure nevertheless
remains a progressive disease with high morbidity and mortality.
Interventions in metabolic remodeling therefore represent a
promising therapeutic adjunctive for targeting pathological
cardiac hypertrophy and development of heart failure (Ardehali
et al, 2012).
Liver X receptors (LXRs) are nuclear receptors that have emerged
as central metabolic regulators in various organ systems and cell
types. At the molecular level, LXRs function as ligand-activated tran-
scription factors that intricately regulate and coordinate cholesterol
homeostasis, glucose and lipid metabolism, and inflammatory
signaling. As such, the importance of LXRs in the cardiovascular
system is mainly attributed to their atheroprotective effects in accel-
erating reverse cholesterol transport (Naik et al, 2006; Zhang et al,
2012), and reducing atherosclerotic lesion size and inflammation
(Schuster et al, 2002; Joseph et al, 2003; Giannarelli et al, 2012).
The biological functions of LXRs are mediated via two subtypes,
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LXRa (NR1H3), which is predominantly expressed in liver, adipose,
intestine, and macrophages, but also in heart, kidney, adrenal
gland, and lung, and LXRb (NR1H2), expressed ubiquitously (Chen
et al, 2005). LXRs reside in the nucleus where they heterodimerize
with retinoid X receptor and are bound to cognate LXR response
elements (LXREs) in regulatory regions of target genes (Peet et al,
1998).
Less is known regarding the role of LXR in pathological
cardiac hypertrophy. LXRs have been implicated in blood pres-
sure control by regulating renin gene expression in vivo (Morello
et al, 2005). In blood pressure-independent models, the LXR
agonist, T0901317 (T09), attenuated the hypertrophic response to
pressure overload in mice (Kuipers et al, 2010), whereas this
effect was exacerbated in LXRa-null mice (Wu et al, 2009).
These studies, however, are limited by confounding systemic
effects of pharmacological LXR activation and by the lack of
agonist specificity. Therefore, it remains unclear whether LXRa
directly affects the pathogenesis of hypertrophy. The purpose of
the present study was to investigate the cardiospecificity of LXRa
in modulation of myocardial metabolism and pathological hyper-
trophy by generating a murine model of cardiac-specific LXRa
overexpression.
Results
Mice with cardiac-specific LXRa overexpression exhibit no overt
cardiac phenotype at baseline or with aging
To study LXRa activation in the heart, we generated transgenic
(LXRa-Tg) mice with cardiac-specific overexpression of murine
LXRa driven by the cardiomyocyte-specific aMHC promoter
(Fig 1A). LXRa mRNA and protein expression were increased
130-fold and 9-fold, respectively (Fig 1B, C and D). Heart weight
in LXRa-Tg mice, as assessed by LV weight normalized to tibia
length (LV/tibia), was marginally less compared to Wt (Fig 1E).
Mean arterial pressure (MAP) was unaltered in LXRa-Tg mice
(Fig 1F). Echocardiography-determined LV dimensions and func-
tion were comparable to Wt, and no differences in indices of
contractility and intracardiac pressures, measured in situ with
microtip catheterization, were observed (Supplementary
Table S1). Histological analyses of ventricular sections stained
with WGA-FITC or Masson’s trichrome displayed no evidence of
abnormal cardiomyocyte morphology or collagen deposition in
LXRa-Tg hearts (Fig 1G). To verify whether overexpression
indeed induced functionally active LXRa, we determined mRNA
levels of well-described LXRa target genes (Tontonoz & Mangels-
dorf, 2003) including Srebp1c, Scd1, and Abca1. These were
significantly increased in LXRa-Tg mice (Fig 1H). Furthermore,
Pgc1a, a co-activator of LXR (Oberkofler et al, 2003), was also
upregulated, plausibly to maintain LXRa in a constitutively active
state. Lxrb expression was not changed. The long-term effects of
cardiac-specific LXRa activation were also assessed in mice up to
12 months of age. Chronic LXRa activation did not impair gross
cardiac morphology or function in aged mice (Supplementary
Table S1). In summary, LXRa-Tg mice displayed normal physio-
logical development, and all structural and functional cardiac
parameters were within normal range.
LXRa overexpression attenuates pathological development of
cardiac hypertrophy, fibrosis, and dysfunction
To evaluate specific effects of LXRa in pathological cardiac hyper-
trophy, mice were subjected to pressure overload by TAC for
5 weeks. Heart weights were similar between sham-operated Wt
and LXRa-Tg groups (Fig 2A). TAC caused significant increases in
LV/tibia ratios; however, LXRa-Tg mice exhibited 24% less hyper-
trophy compared to Wt, which was further evidenced by reduced
cardiomyocyte size (Fig 2B and C). In comparison with LXRa-Tg
mice, the greater degree of hypertrophy observed in Wt was attribu-
table to larger increases in interventricular septal and LV free wall
thicknesses, while no marked dilatation of the LV chamber was
observed for either TAC group (Supplementary Table S2). To further
assess the impact of LXRa on other parameters of myocardial
remodeling, fibrosis was quantified in cross-sectional LV. Collagen
deposition was only marginally detected in LXRa-Tg hearts follow-
ing TAC, whereas this increased 4-fold in Wt (Fig 2C and D). These
anti-fibrotic effects were associated with less induction of genes
involved in fibrogenesis, Col1a1 and Ctgf (Fig 2E). Following TAC,
typical reactivation of the fetal gene program occurred in both
groups, but to a lesser extent in LXRa-Tg mice (Fig 2E). Interest-
ingly, we observed elevated basal levels of natriuretic peptides, Anp
and Bnp, in LXRa-Tg mice. In contrast, other gene markers repre-
sentative of fetal gene activation were more strongly induced in Wt
following TAC: aMHC to bMHC isoform transition (Myh6/Myh7
ratio), Acta1, as well as the hypertrophic gene, Rcan1.
Functional evaluation revealed that Wt mice subjected to TAC
achieved significantly less systolic LV thickening and demon-
strated greater acceleration toward heart failure as fractional
shortening declined 11% versus only 6% in LXRa-Tg (Fig 3A).
These functional improvements in LXRa-Tg mice were further
accompanied by reduced intracardiac pressures (Fig 3C and D).
No changes in MAP or HR were recorded (Fig 3B, Supplementary
Table S2).
To determine whether cardiac LXRa overexpression affects early
hypertrophic remodeling processes, mice were subjected to 1 week
of TAC-induced pressure overload. Cardiac hypertrophy was present
in Wt mice after 1 week of TAC; however, this was significantly
attenuated in LXRa-Tg mice (Supplementary Fig S1A). Assessment
of cardiac function with echocardiography indicated that function
remained relatively compensated in TAC-operated mice (Supple-
mentary Fig S1B). The effect of cardiac LXRa on hypertrophy,
including expression of fetal genes (Supplementary Fig S1C), is
comparable to what we observed in TAC after 5 weeks. Molecular
determinants of inflammation were more strongly upregulated in
Wt hearts compared to LXRa-Tg (Supplementary Fig S1D–G),
whereas the anti-apoptotic factor, Bcl2, was significantly induced
with LXRa overexpression (Supplementary Fig S1I and J). These
data implicate an anti-inflammatory role for LXRa in the initial
phase of hypertrophic pathogenesis, and possible protection against
anti-apoptotic triggers.
To further verify that our observations were not model depen-
dent, we conducted experiments with Ang II infusion over 10 days.
Consistent with our findings from TAC experiments, LXRa-Tg mice
showed reduced Ang II-induced myocardial hypertrophy and fibro-
sis with moderate improvements in hemodynamic parameters
(Supplementary Fig S2). Taken together, these data demonstrate
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that cardiac-specific LXRa activation ameliorates adverse cardiac
remodeling and dysfunction in mice in response to diverse patholog-
ical hypertrophic stimuli.
LXRa overexpression induces transcriptional alterations in
metabolic pathways
Gene profiling of the LV transcriptome was performed to uncover
the molecular basis for the cardioprotective phenotype observed in
LXRa-Tg mice (Supplementary Fig S3, Supplementary Table S3).
Basal LXRa overexpression induced substantial changes in genes
relating to metabolism (Fig 4A). To further investigate microarray
pathway analysis, mRNA levels of several key genes regulating FA
and glucose metabolism were determined (Supplementary Fig S4).
In LXRa-Tg hearts, glycolysis-related genes were more differentially
expressed, including upregulation of the glucose transporters, Glut1
and Glut4, as well as Pdk4, regulating pyruvate oxidation in
mitochondria.
A
C
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Figure 1. Baseline characterization of mice with cardiac-specific LXRa overexpression.
A Murine LXRa DNA construct for the generation of transgenic (LXRa-Tg) mice.
B–D Left ventricular LXRa expression in Wt and LXRa-Tg mice aged 12 weeks. (B) Western blot of LXRa in liver and LV tissue. Quantification of (C) mRNA expression
(normalized to 36b4; n = 6–8/group, *P < 0.00001 versus Wt) and (D) protein expression (normalized to GAPDH; n = 4/group, *P = 0.0001 versus Wt).
E LV weight to tibia length ratios (LV/tibia); n = 15/group. *P = 0.02.
F Assessment of mean arterial pressure (MAP) with in situ catheterization shows no significant differences.
G Representative Masson’s trichrome and wheat germ agglutinin (WGA)-FITC staining in cross-sectional LV, scale bars = 100 lm and 10 lm, respectively.
H Relative mRNA levels of known LXRa-associated and target genes assessed with RT–PCR; n = 8/group. *P = 0.0003, #P = 0.0004, §P = 0.043, †P = 0.0009
versus Wt.
Data information: Data are means  SEM; Student’s paired 2-tailed t-test was used to compare groups.
Source data are available online for this figure.
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TAC provoked parallel transcriptional alterations in Wt and
LXRa-Tg mice, downregulating FA metabolism and similarly
upregulating pathways pertaining to extracellular remodeling and
cardiovascular disease. However, the comparison between differen-
tially expressed genes in hypertrophic hearts was most striking for
LXRa-Tg where more than 50% of upregulated genes clustered into
A
B
E
D
C
Figure 2. LXRa overexpression attenuates TAC-induced cardiac hypertrophy and fibrosis after 5 weeks.
A LV/tibia ratios in sham- and TAC-operated Wt and LXRa-Tg mice; n = 21 Wt sham, n = 24 LXRa-Tg sham, n = 24 Wt TAC, n = 26 LXRa-Tg TAC. *P < 0.00001 versus
respective sham, #P = 0.00004.
B Quantification of cardiomyocyte cross-sectional area from WGA-FITC-stained histological sections; n = 5 Wt sham, n = 4 LXRa-Tg sham, n = 5 Wt TAC, n = 3 LXRa-Tg
TAC. **P = 0.00001 versus Wt sham, *P = 0.01 versus LXRa-Tg sham, #P = 0.01.
C Representative LV sections stained with WGA-FITC and Masson’s trichrome to assess cardiomyocyte hypertrophy and fibrosis, respectively; scale bars = 1 mm,
100 lm, 10 lm, from top to bottom.
D Whole area percentage of fibrosis in Masson’s trichrome-stained sections; n = 8 per group, except n = 7 in Wt TAC group. *P = 0.02 versus Wt sham, #P = 0.02.
E Measurement of mRNA levels with RT–PCR to assess induction of fetal gene program, as well as hypertrophy (Rcan1) and fibrosis (Col1a1, Ctgf); n = 8 per group,
except n = 7 in Wt TAC group. Myh6/Myh7: *P = 0.0001 versus Wt sham, #P = 0.00001; Anp: *P = 0.0005 versus LXRa-Tg sham, #P = 0.02; Bnp: *P = 0.0006 versus
Wt sham, **P = 0.009 versus LXRa-Tg sham, #P = 0.03; Acta1: §P < 0.00001 versus Wt sham, *P = 0.01 versus LXRa-Tg sham, #P = 0.001; Rcan1: **P = 0.00004
versus Wt sham, *P = 0.05 versus LXRa-Tg sham, #P = 0.04; Col1a1: *P = 0.00003 versus Wt sham; Ctgf: §P < 0.00001 versus Wt sham, #P = 0.00001.
Data information: Data are means  SEM; one-way ANOVA with Bonferroni’s multiple comparison test was used to compare groups.
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metabolic pathways, for example, glutathione metabolism. Collec-
tively, these expression data convey that LXRa activation transcrip-
tionally reprograms metabolic pathways in the heart, specifically
glucose metabolism.
Constitutive LXRa activation enhances myocardial glucose
uptake and utilization
We next evaluated whether global transcriptional changes relating
to glucose metabolism translated into a functional metabolic
outcome. To this end, in vivo glucose uptake measurements were
performed in a separate sham/TAC cohort (n = 22) by injecting
mice with FDG and using microPET imaging modality. Basal
myocardial FDG-glucose uptake was 1.9-fold higher in LXRa-Tg
mice compared to Wt, indicating a greater propensity for glucose
utilization. Consistent with previous reports showing a substrate
shift to glucose following hypertrophic perturbation (Liao et al,
2002; Voelkl et al, 2012), TAC lead to a substantial increase in
FDG-glucose uptake in both groups. Wt mice achieved 90%
increase, which subsequently matched basal LXRa-Tg levels. On the
other hand, TAC-operated LXRa-Tg mice exhibited comparatively
even greater capacity for glucose uptake that was augmented 50%
above both basal LXRa-Tg levels and that of Wt TAC cohorts
(Fig 4B and C). Increased glucose uptake in LXRa-Tg hearts did
not impact systemic blood glucose levels as no significant differ-
ences in basal levels prior to scan, nor under fasted conditions
(Supplementary Table S1), were observed. Furthermore, enhanced
glucose uptake was not stored, but rather utilized since myocardial
glycogen content was unaltered (Fig 4D).
Expression levels of several key proteins involved in substrate
metabolism and regulation were measured. In concert with FDG-
glucose uptake levels, GLUT1 and GLUT4 protein levels were
increased in LXRa-Tg hearts (Fig 4E), suggesting their membrane
translocation and functionality. No appreciable differences between
LXRa-Tg and Wt were observed for hexokinase 2 (HK2), the enzyme
catalyzing the first step in glycolysis, nor phosphorylated-AMPK, a
key metabolic regulator in response to increased workload and ener-
getic stress, as well as for CD36 regulating myocardial FA uptake
(Supplementary Fig S5). In summary, enhanced myocardial glucose
uptake evidenced in LXRa-Tg mice in the stressed and non-stressed
state is associated with induction of GLUT1 and GLUT4.
LXRa-deficient mice manifest reduced myocardial glucose uptake
capacity in response to TAC
To gain further insight into LXRa regulation of myocardial metabo-
lism in cardiac hypertrophy, loss-of-function studies were
performed in LXRa/ mice (Supplementary Table S4). Following
5 weeks of pressure overload, both WT and LXRa/ mice devel-
oped LV hypertrophy (Fig 5A). The relative increases in LV/tibia
ratios were considerably higher for LXRa/ compared to WT, 50%
versus 30%, albeit not significantly different from each other.
Furthermore, LXRa-deficient hearts exhibited a greater tendency
toward cardiac dysfunction (Fig 5B and C). Activation of the fetal
gene program occurred to a similar extent in both LXRa/ and
WT mice (Fig 5D–G).
The metabolic response of LXRa-null hearts to hypertrophic
perturbation was assessed by evaluating myocardial glucose uptake
and GLUT expression. Both GLUT1 and GLUT4 were evidently less
upregulated in LXRa/ hearts in response to TAC (Fig 5H).
Furthermore, FDG-glucose analysis with microPET revealed that
LXRa/ mice demonstrated an inability to normalize the increases
in glucose uptake levels achieved in pressure overload-induced
hypertrophy (Fig 5I and J, Supplementary Fig S6). Myocardial
glucose uptake increased 1.6-fold in WT, but only 1.3-fold in
LXRa/ mice. Overall, loss of LXRa resulted in a more progressive
deterioration of function following TAC that was associated with a
compromised adaptive capacity to augment glucose uptake.
Mitochondrial oxidative capacity of pyruvate is unaltered by
chronic LXRa overexpression
To assess whether LXRa-Tg mice displayed increased mitochondrial
capacity to oxidize glucose-derived substrates, we determined
oxidative phosphorylation in permeabilized LV muscle fibers in the
presence of pyruvate in an additional sham/TAC cohort (n = 26).
Basal (state 2) and maximal ADP-stimulated (state 3) oxygen
consumption rates did not differ among stressed and unstressed
LXRa-Tg and Wt hearts (Supplementary Fig S7A), indicating
that the capacity for pyruvate oxidation was neither impaired
nor enhanced by LXRa overexpression or by TAC. Citrate
synthase activity, a marker of mitochondrial density to which all
A B
C D
Figure 3. Reduced cardiac dysfunction in mice with cardiac LXRa
activation in response to pathological pressure overload.
A Echocardiographic assessment of percent fractional shortening in mice
subjected to 5 weeks of TAC; n = 19 Wt sham, n = 22 LXRa-Tg sham,
n = 24 Wt TAC, n = 26 LXRa-Tg TAC. **P < 0.00001 versus Wt sham,
*P = 0.0005 versus LXRa-Tg sham, #P = 0.009.
B–D Hemodynamic measurements obtained in situ in sham- and TAC-
operated mice; n = 6–8/group. (B) Mean arterial pressure (MAP) showed
no significant differences. (C) LV end-systolic pressure (LVESP).
**P < 0.00001 versus Wt sham, *P = 0.00004 versus LXRa-Tg sham,
*P = 0.003. (D) LV end-diastolic pressure (LVEDP). *P = 0.02 versus Wt
sham.
Data information: Data are means  SEM; one-way ANOVA with Bonferroni’s
multiple comparison test was used to compare groups.
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respirometry measurements were normalized, was similar for all
groups (Supplementary Fig S7B).
Interestingly, we recorded increased state 2 and state 3 respira-
tion rates with palmitoyl (C16)-carnitine in LXRa-Tg, suggesting a
trend toward increased capacity to oxidize FA (Supplementary Fig
S7C). This may be due to a reciprocal effect on pyruvate oxidation
by Pdk4, which was induced in LXRa-Tg (Supplementary Fig S4A).
The respiratory control ratio, indicative of overall mitochondrial
function (Brand & Nicholls, 2011), tended to be higher for palmitoyl-
carnitine in stressed and unstressed hearts overexpressing LXRa
(Supplementary Fig S7D). Further lipid profiling revealed increased
myocardial leanness in LXRa-Tg hearts (Supplementary Fig S8),
despite induction of several lipogenic gene targets (Srebp1c, Scd1,
Fasn) (Fig 1H, Supplementary Fig S4B).
LXRa-mediated glucose uptake increases O-GlcNAc signaling
in cardiomyocytes
Since no differences in mitochondrial capacity to utilize pyruvate
was identified, we postulated that beneficial effects derived from
A
B
D E
C
Figure 4. Cardiac LXRa overexpression enhances myocardial glucose uptake.
A Classification of genes differentially expressed in LXRa-Tg hearts (see Supplementary Fig S3).
B Representative 18F-FDG images with microPET in the coronal and axial planes in Wt and LXRa-Tg mice 5 weeks post-TAC.
C Myocardial FDG uptake measured as standard uptake value (SUV); n = 4–6/group. *P = 0.04 versus Wt sham, **P = 0.02 versus LXRa-Tg sham, #P = 0.03, ##P = 0.01.
D Quantification of myocardial glycogen content shows no significant differences; n = 5 per sham group, n = 7 per TAC group.
E GLUT protein expression in LV tissue normalized to GAPDH; n = 6/group. Glut1: *P = 0.01 versus LXRa-Tg sham, #P = 0.03; Glut4: *P = 0.03 versus LXRa-Tg sham,
#P = 0.01.
Data information: Data are means  SEM; one-way ANOVA with Bonferroni’s multiple comparison test was used to compare groups.
Source data are available online for this figure.
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Figure 5. LXRa-null mice manifest reduced myocardial glucose uptake capacity in response to TAC.
A LV/tibia ratios in sham- and TAC-operated WT and LXRa/ mice; n = 10 WT sham, n = 8 LXRa/ sham, n = 12 WT TAC, n = 10 LXRa/ TAC. *P = 0.006 versus
WT sham, **P = 0.00008 versus LXRa/sham.
B, C Cardiac functional assessment at 5 weeks post-TAC. (B) Percent fractional shortening determined with echocardiography; n = 10 WT sham, n = 7 LXRa/ sham,
n = 12 WT TAC, n = 10 LXRa/ TAC. *P < 0.00001 versus respective sham, §P = 0.06. (C) LV end-diastolic pressure (LVEDP) recorded in situ; n = 10 WT sham,
n = 7 LXRa/ sham, n = 10 WT TAC, n = 9 LXRa/ TAC. *P = 0.001 versus WT sham, **P = 0.00005 versus LXRa/ sham.
D–G Relative mRNA gene expression as determined by RT–PCR, normalized to 36b4; n = 8/group. Anp: no significant differences; Bnp: *P = 0.01 versus WT sham,
**P = 0.03 versus LXRa/ sham; Myh6/Myh7: *P = 0.0002 versus WT sham, **P = 0.0003 versus LXRa/ sham; Acta1: *P = 0.001 versus respective sham.
H Western blot detection of GLUT protein expression in LV tissue normalized to GAPDH, expressed as fold change, shows no significant differences among groups;
n = 6–8/group.
I Representative 18F-FDG-microPET scans.
J Myocardial FDG uptake quantified as standard uptake value (SUV); n = 6/group. *P = 0.0001 versus WT sham, #P = 0.047.
Data information: Data are means  SEM; one-way ANOVA with Bonferroni’s multiple comparison test was used to compare groups.
Source data are available online for this figure.
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LXRa-mediated enhanced glucose uptake involved alternate path-
ways of glycolytic metabolism. One such pathway is the hexosa-
mine biosynthesis pathway (HBP) which culminates in the
formation of O-GlcNAc, a posttranslational modifier of numerous
proteins. The HBP has been demonstrated to be an essential signal-
ing system in the failing heart (Watson et al, 2010), and accumulat-
ing evidence from in vitro and ex vivo systems shows that
augmented O-GlcNAc levels via the HBP potentiates cytoprotection
(Ngoh et al, 2010; Darley-Usmar et al, 2012). Using NRVMs, we
tested the hypothesis that LXRa-mediated increases in glucose
uptake would enhance substrate availability for O-GlcNAc. NRVMs
transfected with Ad-LXRa showed significantly elevated 2-deoxyglu-
cose (2-DG) levels of 1.8-fold compared to Ad-cont cells, which was
further augmented 40% following PE stimulation (Fig 6A). Glut4
and Glut1 mRNA levels were correspondingly increased (Fig 6B and
C). Next, we assessed whether enhanced glucose availability led to
HBP activation and downstream formation of O-GlcNAc. Ad-LXRa
cells displayed increased global protein O-GlcNAcylation that was
further enhanced with PE (Fig 6D). Administration of DON to
inhibit HBP flux attenuated Ad-LXRa-increased O-GlcNAcylation
(Fig 6D), confirming the link between LXRa and HBP-O-GlcNAc
signaling.
From our findings in LXRa-Tg mice, we speculated that increased
myocardial natriuretic peptide expression (Fig 2E) in conjunction
with preference for glucose may, in part, be evidence of an endoge-
nous cardioprotective stress response elicited via LXRa overexpres-
sion. The anti-hypertrophic properties of ANP and BNP are well
established (Nishikimi et al, 2006). Ad-LXRa cells expressed both
increased Anp and Bnp (3.2-fold and 3.8-fold, respectively), which
were subsequently suppressed following DON inhibition, suggesting
that their induction is linked to O-GlcNAc effector signaling (Fig 6E
and F). Further assessment of cellular hypertrophy indicated that
DON inhibition of HBP flux also abolished the Ad-LXRa-mediated
reductions in cell size that was increased upon PE stimulation
(Fig 6G and H).
Alternative experiments were performed with si-LXRa to address
the causal relationship among LXRa expression, protein O-GlcNAc
modification, and hypertrophy. Knockdown of LXRa led to compar-
atively higher levels of hypertrophic growth (Fig 7A), and lower
levels of O-GlcNAc following PE-induced cellular stress (Fig 7B).
Interestingly, gene expression analysis (Fig 7C–F) revealed signifi-
cant downregulation of Anp in LXRa-silenced cells (Fig 7C).
Transcriptional activators of natriuretic peptides are O-GlcNAc
modified in LXRa-Tg hearts
Finally, to corroborate our in vitro findings, we assessed global
protein O-GlcNAc levels from LV tissue lysates of mice overexpress-
ing and deficient for LXRa. Most extensive O-GlcNAcylation was
observed in LXRa-Tg hearts involving proteins between 40 and
55 kDa in size (marked in Fig 8A). In contrast, loss of LXRa resulted
in attenuated O-GlcNAc signal in response to TAC (Fig 8B). To
further identify specific O-GlcNAc targets, agarose wheat germ
agglutinin (WGA) precipitation was performed to isolate nuclear
GlcNAcylated proteins. Using antibodies specific for known tran-
scription factors activating ANP and BNP (Morin et al, 2000; Hayek
& Nemer, 2011), Western blot analysis revealed that GATA4 and
Mef2c precipitated with WGA in LXRa-Tg hearts, but not with
Nkx-2.5, suggesting that O-GlcNAc modification of GATA4 and Mef2c
potentiates their activities (Fig 8C and D). N-acetylglucosamine
(GlcNAc), a competitor, served as a control.
In summary, these data indicate that cardiac LXRa integrates
glucose metabolism and downstream O-GlcNAcylation with induc-
tion of cytoprotective natriuretic peptides to orchestrate an anti-
hypertrophic response. Therefore, the energy-independent effects of
glucose that, herein, are governed by LXRa may be an important
salutary mechanism in modulating and preserving myocyte function
(Fig 9).
Discussion
In the present study, we describe a cardiac-specific overexpression
model for LXRa in mice, and herewith, elucidate the significance of
LXRa in modulating myocardial metabolism in pathological hyper-
trophy. We established that constitutive LXRa activation in murine
hearts substantially diminished LV hypertrophy, adverse cardiac
remodeling, and improved overall cardiac function following
chronic pressure overload and Ang II stimulation. Using this model,
we identified the intrinsic transcriptional regulatory mechanisms
LXRa exerts in the heart and in counteracting hypertrophic stress.
By principally modulating glucose pathways, LXRa functionally
enhanced the capacity for myocardial glucose uptake, which was
conversely impaired in hypertrophic hearts deficient for LXRa.
Furthermore, increased glucose utilization via an energy-indepen-
dent pathway resulted in the glycosylation of transcription factors
inducing natriuretic peptide expression, which we identified as a
putative end effector of LXRa-mediated protective effects in the
heart.
The role of LXRa in protection against cardiac pathophysiology
is not well established. This has been previously addressed in
pharmacological studies using the LXR agonist, T09, and LXRa-null
mice (Wu et al, 2009; Kuipers et al, 2010). Conceivably, these
approaches are restrained by confounding variables associated with
systemic LXR activation, which include lipogenic (Peet et al, 1998),
anti-inflammatory (Zelcer & Tontonoz, 2006), and blood pressure
lowering (Leik et al, 2007) effects. Moreover, T09 mediates its
effects indiscriminately via other nuclear receptors since it is also a
co-activator of farnesoid X receptor, pregnane X receptor, and reti-
noic acid receptor signaling (Houck et al, 2004; Mitro et al, 2007;
Kumar et al, 2010). Selectively overexpressing cardiac LXRa in mice
circumvented these confounding factors and afforded a system for
delineating the heart-specific effects of LXRa. Using two diverse
hypertrophic perturbations, we demonstrated that constitutive LXRa
activation countervailed pathological growth and remodeling
processes in the heart, including blunting the development of
myocardial fibrosis, an observation in line with previous studies
demonstrating the anti-fibrotic effects of LXRs in kidney (Tachibana
et al, 2012) and in liver (Beaven et al, 2011). Cardiac LXRa also
appears to influence early remodeling processes since less inflam-
mation in association with decreased hypertrophy occurred at an
earlier time point of 1 week post-TAC. LXRa-Tg mice may also be
less susceptible to apoptosis, which is underscored by upregulation
of Bcl2. Taken together, counteraction of inflammatory signaling
and myocyte death may explain the attenuated development of
fibrosis remodeling we observed after 5 weeks TAC.
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Figure 6. LXRa enhances glucose uptake and O-GlcNAc signaling via activation of the hexosamine biosynthetic pathway (HBP) in cultured cardiomyocytes.
Neonatal rat ventricular myocytes were transfected with Ad-LXRa or GL2 (Ad-cont), and treatments with phenylephrine (PE) and DON (inhibitor of HBP) were initiated for
24 h.
A Assessment of 2-deoxyglucose (2-DG) uptake from 4 independent experiments. *P = 0.03 versus Ad-cont.
B, C Glut mRNA expression determined by RT–PCR normalized to 36b4, n = 5 per condition in the absence of PE, n = 4 per condition in the presence of PE. *P = 0.02
versus Ad-cont, **P = 0.008 versus Ad-cont, #P = 0.03, ##P = 0.008.
D Western blot indicating Ad-LXRa- and PE-induced increases in global protein O-GlcNAcylation, which was abrogated following inhibition of HBP with DON. LXRa
protein expression is shown, and GAPDH served as a loading control.
E, F Modulation of Anp and Bnp mRNA levels by Ad-LXRa-induced O-GlcNAc signaling. Gene expression as determined by RT–PCR normalized to 36b4, n = 5 per
condition in the absence of PE, n = 4 per condition in the presence of PE. *P = 0.02 versus Ad-cont, **P = 0.008 versus Ad-cont, #P = 0.03, ##P = 0.02.
G Measurement of cell size, n = 5 per condition. *P = 0.008 versus Ad-cont, #P = 0.02, ##P = 0.03.
H Representative images for the determination of cell size. Cells were stained with an antibody specific for LXRa (green, indicated by arrow), DAPI for nuclei (blue),
and rhodamine-phalloidin for F-actin (red); scale bar = 50 lm.
Data information: Data are means  SEM and are reported as fold change with respect to control group; Kruskal–Wallis test followed by Mann–Whitney U-test was
used for group comparisons.
Source data are available online for this figure.
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In loss-of-function studies, LXRa/ mice did not develop signifi-
cantly greater severity of hypertrophy with respect to WT, although
function was worsened in LXRa-deficient hearts. This is in contrast
to a previous report showing exacerbated hypertrophic response in
LXRa/ mice (Wu et al, 2009). The discrepancy between LXRa
overexpression and deficiency cannot be fully explained herein;
however, our in vitro data indicate that, at the cellular level, there is
a clear effect on hypertrophic growth in cardiomyocytes lacking
LXRa, and thus, compensatory mechanisms may be operative in the
intact heart. Interestingly, recent evidence from a genome-wide
association study (GWAS) of electrocardiographic LV hypertrophy
(LVH) found a genetic variant, or SNP, in the LXRa (Nr1h3) locus to
be significantly associated with the LVH trait. Furthermore, expres-
sion QTL analysis showed a significant correlation between
decreased expression of Nr1h3 and increased LVH (P. Van der Harst,
unpublished data, 2011), supporting an anti-hypertrophic role for
LXRa.
Functionally, gene profiling in our model of cardiac-specific
LXRa overexpression identified primary effects for LXRa on
metabolic pathways, and further investigation into this metabolic
profile revealed that myocardial glucose uptake in association
with GLUT expression was significantly increased in LXRa-Tg
hearts and in isolated cardiomyocytes. GLUT1 and GLUT4 have
previously been elucidated as targets for transcriptional regula-
tion by LXRs in adipose tissue and skeletal muscle (Ross et al,
2002; Dalen et al, 2003; Laffitte et al, 2003; Kase et al, 2005;
Griesel et al, 2010). Myocardial glucose uptake capacity was
enhanced in LXRa-Tg mice, and more importantly, when chal-
lenged with hypertrophic stress, these mice demonstrated an even
more robust response versus that of Wt. Conversely, insufficient
glucose uptake capacity that ensued in hypertrophic hearts defi-
cient for LXRa resulted in a worsened functional outcome. The
shift toward greater glucose reliance is believed to be an adap-
tive response that confers cardioprotection (Opie & Knuuti, 2009;
Kolwicz & Tian, 2011), and evidence from other genetic mouse
models renders further support for a role for glucose uptake in
myocardial protection. Cardiac-specific overexpression of GLUT1
in mice increased glucose uptake and glycolysis which prevented
the development of ventricular dysfunction and improved
survival (Liao et al, 2002; Luptak et al, 2005), whereas reduced
glucose utilization in GLUT4 knockout mice manifested greater
hypertrophy and acceleration toward heart failure (Katz et al,
A
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Figure 7. Knockdown of LXRa increases cellular hypertrophy in cultured cardiomyocytes.
Cells were transfected with Ad-LXRa, si-LXRa, or Ad-cont, in the absence or presence of phenylephrine (PE).
A Protein synthesis determined via leucine incorporation, n = 2–4 independent experiments. *P = 0.03 versus Ad-cont, §P = 0.06 versus Ad-cont.
B Global O-GlcNAc protein expression with Western blot, GAPDH served as a control.
C–F mRNA expression, normalized to 36b4, n = 6 per condition, except n = 5 for si-LXRa control. Anp: *P = 0.009 versus Ad-cont, #P = 0.004, ##P = 0.009; Bnp:
*P = 0.004 versus Ad-cont, **P = 0.002 versus Ad-cont; Acta1: *P = 0.002 versus Ad-cont, §P = 0.06 versus Ad-cont, #P = 0.02; Rcan1: *P = 0.03 versus Ad-cont,
**P = 0.004 versus Ad-cont, #P = 0.004.
Data information: Data are means  SEM and are reported as fold change with respect to control group; Kruskal–Wallis test followed by Mann–Whitney U-test was
used for group comparisons.
Source data are available online for this figure.
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1995; Domenighetti et al, 2010). With cardiac insulin resistance and
metabolic dysregulation known to precede the development of heart
failure (Witteles & Fowler, 2008; Brouwers et al, 2013), strategies
sensitizing the heart to glucose uptake may thus have clinically
relevant implications in the long-term prognosis of heart failure.
Since glucose uptake rates were enhanced by LXRa activation,
we hypothesized that this would also lead to downstream changes
in energy-dependent pathways, causing increased mitochondrial
oxidative capacity. However, we did not observe corresponding
increases in oxidative capacity from pyruvate, suggesting that LXRa
does not transcriptionally reprogram pathways for the enhancement
of mitochondrial glucose utilization. In essence, excess glucose
uptake and glycolysis appears to be partially uncoupled from mito-
chondrial oxidation and ATP synthesis in LXRa-Tg hearts, possibly
via a regulatory effect of LXRa on Pdk4, which negatively regulates
pyruvate dehydrogenase complex (PDC) activity. This is in contrast
to previous reports showing that, in the protection against cardiac
stress, GLUT1 overexpression corrected insufficient glucose utiliza-
tion and oxidation caused by PPARa deficiency in mice (Luptak
et al, 2005), and preserved mitochondrial energetic status (Liao
et al, 2002). That glucose oxidative capacity is not increased in
LXRa-Tg hearts may be due to the fact that mitochondrial oxidation
rates are indeed normal and not compromised, and since myocar-
dial contractility is unimpaired is evidence that ATP supply is
sufficient to fuel contraction. Consequently, excess glucose uptake
is neither stored nor oxidized, but is instead diverted into other
glycolytic functions due to a modulatory effect of Pdk4.
Currently, the role of glucose signaling independent of its energy-
providing effects is largely unaddressed in the hypertrophic and
failing heart, but has been implicated to play an important role in
myocyte function and survival (Kolwicz et al, 2013). Moreover, the
fate of glucose is of interest given that increased glucose uptake and
glycolysis in cardiac hypertrophy do not always result in concomi-
tant increases in glucose oxidation (Allard et al, 1994; Wambolt
et al, 1999; Doenst et al, 2013). Our data indicate that, by enhancing
glucose flux, cardiac LXRa activates an ancillary pathway of glycoly-
sis, the HBP, increasing levels of the posttranslational modifier,
O-GlcNAc. Further, we establish that this pathway induces transcrip-
tion of natriuretic peptides via glycosylation of GATA4 and Mef2c,
transcriptional activators of ANP and BNP (Morin et al, 2000). It is
interesting that LXRa-Tg hearts exhibit increased basal ANP and
BNP mRNA levels without inducing the complete fetal gene
A B
C D
Figure 8. O-GlcNAcylation is increased with cardiac LXRa overexpression in mice.
A, B Western blot analyses of global protein O-GlcNAc levels in left ventricles of mice with either (A) cardiac-specific LXRa overexpression or (B) LXRa deficiency and
subjected to 5 weeks TAC.
C, D Nuclear protein extracts were precipitated with agarose WGA in the absence or presence of GlcNAc, a competitor, and analyzed by Western blot with antibodies
against Mef2c, GATA4, or Nkx-2.5, known transcription factors of natriuretic peptides; bands represent 3 pooled hearts per Wt and LXRa-Tg lanes, and
(D) quantification is for n = 2, expressed as fold change.
Data information: Data are means  SEM. IP, immunoprecipitation; WGA, wheat germ agglutinin; GlcNAc, N-acetylglucosamine; WB, Western blot.
Source data are available online for this figure.
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response or displaying signs of cardiac dysfunction normally associ-
ated with their induction, suggesting that the expression of indivi-
dual fetal genes is indeed regulated by distinct signal mechanisms.
Nevertheless, the cardioprotective effects of natriuretic peptide
signaling are well established (Nishikimi et al, 2006), and murine
models with ablated natriuretic peptide signaling show increased
propensity for cardiac hypertrophy and myocardial fibrosis (Tamura
et al, 2000; Holtwick et al, 2003; Wang et al, 2003). Therefore, the
anti-hypertrophic and anti-fibrotic potential of local ANP and BNP
signaling may largely contribute to the protective phenotype
observed in LXRa-Tg mice, an adaptive response mediated via
transcriptional control of glucose-O-GlcNAc-dependent signaling by
cardiac LXRa. Future studies aimed at elucidating additional
O-GlcNAc targets should provide further insight into the link
between myocyte metabolism and survival in the diseased heart.
In clinical cardiology, progressive cardiac remodeling often tran-
sitions into overt symptomatic heart failure, and although several
effective treatments have been developed to prevent this transition,
there remains a high residual risk. Alterations in myocardial
substrate metabolism contribute to this progression; however, no
metabolic modulators are part of the guideline-based therapy for
heart failure. Promising pharmacological agents such as trimetazi-
dine and perhexiline inhibit FA oxidation and indirectly cause a
reciprocal shift to glucose utilization, yet drugs for direct glucose
enhancement are not available. Our data indicate that targeting
LXRa as a metabolic intervention to increase glucose metabolism
profoundly influenced cardiac hypertrophy and remodeling, inde-
pendent of hemodynamic or neurohormonal effects.
In conclusion, this study demonstrates that LXRa confers heart-
specific protective effects in the attenuation of pathological LV
hypertrophy and preservation of cardiac function. We identify LXRa
as an important cardiac transcriptional regulator that further
promotes the adaptive capacity for glucose uptake and utilization in
cardiac hypertrophy. Furthermore, this study highlights the under-
recognized potential for non-energy-dependent pathways of glycoly-
sis such as the HBP in promoting cytoprotection. New generation
LXR agonists with less lipogenic profiles are currently being devel-
oped, and we postulate that such agonists may be useful modulators
of myocyte metabolism in the prevention of pathological cardiac
remodeling and heart failure.
Materials and Methods
For more detailed Methods, see the Supplementary Information.
Animal models
The murine NR1H3 gene (GeneBank: NM_013839) was obtained
from German Science Centre for Genomic Research (RZPD; clone #
IRAVp968B0923D). This PCR product was amplified by polymerase
chain reaction (PCR) and cloned into a previously described vector
containing the cardiac-specific aMHC promoter (Gulick et al, 1991).
Transgenic founders were obtained by pronuclear injection of the
aMHC-LXRa construct into FVB oocytes. Transgene identification
was performed by a PCR-based method using the following primers:
sense 50-CGGCACTCTTAGCAAACCTC-30, antisense 50-TGCTGACTC
CAACCCTATCC-30. Mice were backcrossed for at least three genera-
tions into the C57BL/6 (#000664, The Jackson Laboratory) genetic
background. aMHC-LXRa (LXRa-Tg) mice were generated by the
UMCG mouse clinic in collaboration with the Mayo Clinic (Rochester,
NY, USA). For all experiments, non-transgenic littermates (Wt)
served as controls.
Homozygous LXRa knockout mice (LXRa/; gift from Dr.
Gustafsson) (Alberti et al, 2001) and matching C57BL/6BomTac
wild-type (WT) mice were obtained from Taconic, Denmark.
Experimental protocol
All experimental protocols were approved by the Institutional
Animal Care and Use Committee at the University of Groningen.
Male mice (8–10 weeks) were subjected to an infusion of angio-
tensin II (Ang II) (1.0 mg/kg/day) for 10 days, or pressure overload
by transverse aortic constriction (TAC) for either 1 or 5 weeks. In
subsequent studies, a subset of mice underwent sham/TAC for
5 weeks for further assessment of myocardial 2-deoxy-2-(18F)fluoro-
D-glucose (FDG)-glucose uptake with microPET, or mitochondrial
oxidative phosphorylation measurements. Cardiac function was
determined with echocardiography and invasive hemodynamic
monitoring, as previously described (Yu et al, 2013). LV tissue
samples were used to perform expressional studies, immunohisto-
chemical, and biochemical analyses.
In vitro studies
Neonatal rat ventricular myocytes (NRVMs) were isolated from 1- to
3-day-old Sprague Dawley pups, as described (Lu et al, 2012).
Recombinant adenovirus containing murine LXRa (Ad-LXRa) or
silenced LXRa (si-LXRa) was used to infect NRVMs, and cells were
Figure 9. Schematic representation of LXRa-mediated glucose
protection.
LXRa transcriptionally regulates glycolytic metabolism by targeting glucose
utilization at distinct levels. Increased Glut1 and Glut4 enhance glucose uptake,
and Pdk4 regulates pyruvate oxidation in mitochondria. Subsequent increases in
glycolytic flux activate the HBP, resulting in downstream O-GlcNAc modification
of transcription factors inducing natriuretic peptide expression, a putative end
effector mediating anti-hypertrophic effects in the heart. ANP, atrial natriuretic
peptide; BNP, B-type natriuretic peptide; F-6-P, fructose-6-phosphate; Glut,
glucose transporter; HBP, hexosamine biosynthesis pathway; Mef2c, myocyte
enhancer factor 2C; O-GlcNAc, b-O-linkage of N-acetylglucosamine; PDC,
pyruvate dehydrogenase complex; Pdk4, pyruvate dehydrogenase kinase 4.
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treated with phenylephrine (PE) or 6-diazo-5-oxonorleucine (DON)
(Sigma). Cellular glucose uptake and protein synthesis were
assessed with 2-deoxyglucose (2-DG) and [3H]leucine assays,
respectively.
Statistical analysis
All data are presented as means  standard error of the mean
(SEM). Student’s paired 2-tailed t-test was used for two group
comparisons. One-way ANOVA was performed to analyze differ-
ences for multiple-group comparisons, followed by Bonferroni post
hoc analysis. Kruskal–Wallis test followed by Mann–Whitney U-test
was used to analyze cell experiments. All results were tested at the
P < 0.05 level of significance.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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